Omitting radiation for advanced lung cancer patients who responded to treatment

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study investigates the effects of omitting clinical target volume (CTV) radiation in patients with locally advanced non-small cell lung cancer (NSCLC) who have responded to induction therapy with immunotherapy and chemotherapy. The aim is to reduce the incidence of pneumonitis, a common side effect of radiotherapy, while maintaining effective local control of the cancer. By optimizing the radiotherapy approach, the study seeks to enhance immune function and improve patient outcomes. Participants will be monitored for their response to treatment and any adverse effects.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Histologically or cytologically confirmed non-small cell lung cancer;
2. stage IIIA or IIIB or IIIC according to the 8th edition of the TNM cancer staging system of the American Joint Committee on Cancer (AJCC) and Union for International Cancer Control（UICC);
3. inoperable or refuses surgery after induction therapy with immunotherapy and chemoradiotherapy;
4. After ≥2 cycles of induction chemotherapy combined with immunotherapy, the efficacy was CR, PR or SD (with a decreasing trend);
5. performance status 0-1;
6. measurable or evaluable lesions;
7. Survival expectancy is not less than 6 months;
8. adequate cardiac, pulmonary, renal, and hepatic and bone marrow function

Exclusion Criteria:

1. tumor progress after induction with immunothearoy and chemotherapy
2. EGFR, ALK, or ROS1 mutation;
3. Previous thoracic radiotherapy;
4. grade 2 or more immune-related adverse events after induction immunotherapy
5. Previous malignancies (except stage I non-melanic skin cancer or cervical carcinoma in situ);
6. Pregnant or lactating women
7. undergoing other clinical trials;
8. Have serious comorbidities, including myocardial infarction, severe arrhythmia, severe cerebrovascular disease, ulcer disease, psychosis and uncontrollable diabetes;
9. Patients with HIV positive and undergoing antiviral therapy;
10. Active tuberculosis

Where it's running

• Hubei Cancer Hospital
  Wuhan, Hubei, China Recruiting

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Short-Course Radiotherapy Followed by CAPOX With or Without Iparomlimab and Tuvonralimab in Localized Rectal Cancer

  In people with locally advanced, treatment-naive rectal cancer, this study tests whether adding two immunotherapy drugs to a standard chemotherapy after short-course radiotherapy can improve tumor response.

  Recruiting Phase 3 Shandong Cancer Hospital and Institute · Jinan, Shandong · NCT07686640

• Prospective cohort of SCLC patients receiving radiotherapy-based comprehensive treatment

  This project will collect detailed clinical, imaging, pathology, and molecular data from adults with limited-stage SCLC who receive radiotherapy with or without chemotherapy and immunotherapy to try to identify which radiotherapy timing, dose, and combinations work best.

  Recruiting Shanghai Chest Hospital · Shanghai, Shanghai Municipality · NCT07565532

• Ivonescimab in Neoadjuvant NSCLC: Testing a PD-1/VEGF Bi-specific

  This study tests Ivonescimab, a PD-1/VEGF bispecific antibody, in people with non-small cell lung cancer to see if it works better or has different safety than standard PD-1 inhibitors before surgery.

  Recruiting Peking University People's Hospital · Beijing, Beijing Municipality · NCT07359040

• Exercise training and the immune response in lung cancer

  This study tests whether a 12-week moderate or high-intensity exercise program can change the immune markers in people with non-small cell or small cell lung cancer who are receiving standard care.

  Recruiting Medical University of Graz · Graz · NCT07267000

• β-hydroxybutyrate with short-course radiotherapy, immunotherapy and CAPEOX before surgery for locally advanced rectal cancer

  This phase II trial will test whether adding β-hydroxybutyrate supplements to short-course radiotherapy followed by immunotherapy plus CAPEOX chemotherapy improves outcomes for people with locally advanced rectal cancer before surgery.

  Recruiting Phase 2 Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · Wuhan, Hubei · NCT07239466

• Neoadjuvant radiotherapy plus SOX chemotherapy with Iparomlimab and Tuvonralimab for resectable gastric and gastroesophageal junction adenocarcinoma

  This trial will test whether adding radiotherapy to pre-surgery SOX chemotherapy plus two immunotherapy drugs (Iparomlimab and Tuvonralimab) helps people with resectable, HER2‑negative gastric or gastroesophageal junction cancer.

  Recruiting Phase 2 Daping Hospital and the Research Institute of Surgery of the Third Military Medical University · Chongqing, Other (Non U.s.) · NCT07165847

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.